Jump to content

Cadila Pharmaceuticals

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dl2000 (talk | contribs) at 02:11, 3 August 2018 (→Products & Services: fix hdg). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

CADILA Pharmaceuticals Limited
Company typePrivate company
IndustryPharmaceuticals
Founded1951
FounderMr.Indravadan A. Modi
Headquarters
Ahmedabad, Gujarat
,
India
Key people
Dr. Rajiv Modi
(Chairman and Managing Director)
ProductsBranded Formulations, Generic drugs
ServicesContract Research, Contract Manufacturings
Websitewww.cadilapharma.com

Cadila Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat, founded in 1951. Cadila Pharmaceuticals manufactures and sells finished formulations and active pharmaceutical ingredients (APIs) in 100 countries. The company offers formulations across therapeutic areas, such as cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals.

Company

Cadila Laboratories was established by Mr. Indravadan A. Modi along with Mr. Raman Patel in 1951 in Ahmedabad. In 1995 the company was restructured into two separate companies. These were Cadila Pharmaceuticals to be managed by Mr. Indravadan Modi and Cadila Healthcare which went to his former partner Mr. Raman Patel. Dr. Rajiv Modi, son of Mr. Indravadan Modi is the current chairman and managing director of Cadila Pharmaceuticals Limited.[1]

Manufacturing

Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia). The 2 API manufacturing facilities are located at Ankleshwar, Gujarat.

The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.[2]

Cadila Pharmaceuticals started its Agro division in 1992.[citation needed]

Accreditations

Cadila Pharmaceuticals manufacturing facilities are accredited by WHO-GMP, WHO- Geneva (GDF site for Anti-TB), USFDA, TGA Australia (PIC/S), MHRA-UK, MCC-South Africa, ISO 9001 and ISO 14001.[3]

Research

Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is manned by 300 scientists.

The firm is the first Indian company to get Investigational New Drug (IND) approval by USFDA for clinical trials to be conducted in India. [citation needed] The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs.[4] Cadila Pharmaceuticals has connections with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi; Institute of Microbial Technology, Chandigarh; Talwar Research Foundation, New Delhi and Trieste, Italy.[5]

Products and services

Cadila Pharmaceuticals offers branded and generic formulations covering more than 45 therapeutic segments and 12 specialties. It also offers more than 50 APIs and intermediates. In the services realm, the company offers Contract Research and Contract Manufacturing.

Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – ‘Rabeloc’.[6] In 2009, the world’s first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – ‘Risorine’[7] and world's first drug combination for prevention of Cardiovascular Diseases – ‘Polycap’ were introduced by Cadila Pharmaceuticals.[8] For the patients suffering from Non Small Cell Lung Cancer (NSCLC), company has recently introduced ‘Mycidac-C’ - first in the class active immunotherapy as well as drug targeting Desmocollin.[9] Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D and Mycobutol

References

  1. ^ Business Standard 28 January 2014
  2. ^ Financial Express 28 January 2013
  3. ^ Cadila Pharma
  4. ^ Ministry of External Affairs
  5. ^ Cadila Pharma
  6. ^ Business Standard 16 July 2004
  7. ^ DNA 31 October 2009
  8. ^ Financial Express 2 April 2009
  9. ^ Economic Times 21 November 2013
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cadila_Pharmaceuticals&oldid=853194108"